Search

Applying advanced technologies to bioprocessing operations will only help improve success rates.

How RNA is making waves in the industry – and leading to new research projects and increased demand for new manufacturing capacities.

Jan Cools of the VIB Center for Cancer Biology discusses his experience with Mission Bio’s new DNA sequencing platform.

Oligonucleotide-based therapeutics have been investigated over the last decades and their promise as a new drug modality is now being realized.

After a madcap back and forth between leading and dissenting Democrats, Biden’s drug pricing reform plans have reached a compromised final form.

Antibody drug conjugates are starting to transform cancer treatments, so let’s maintain the momentum.

Stating an intention to be ready to win in any biowarzone, the US military has commissioned Dynavax to develop a vaccine for the plague.

In a market filled with complexity, working with a single supplier simplifies the supply chain and focuses effort towards a single target.

A possible fix for problems in small molecule manufacture via continuous flow processing.

The FDA has approved just three biosimilars in 2021 – but the approvals could shake up the field as discussions around interchangeability intensify.